All In Biotech

Drug Trial Radar · NCT06953063

A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study To Evaluate The Efficacy And Safety Of DA-302168S Tablets In Overweight/Obese Subjects

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

250

Actual

Start

May 15, 2025

Primary completion

Dec 15, 2025

Study completion Dec 15, 2025

Sponsor

Sponsor type
Industry
First posted
May 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of DA-302168S tablets in overweight and obese adults.

Conditions

  • Overweight and Obesity

Interventions

  • DA-302168SDrug

    A small molecule GLP-1R agonist tablet, orally administration, once daily,16weeks.

  • Placebo of DA-302168SDrug

    Matching placebo tablet will be provided

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. percentage change in body weightTime frame: From baseline (week1) to week16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.